AXIS CAPITAL HOLDINGS LIMITED (AXS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $99.52, AXIS CAPITAL HOLDINGS LIMITED (AXS) is priced for 10.0% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/AXS

Headline

FieldValue
TickerAXS
CompanyAXIS CAPITAL HOLDINGS LIMITED
Sector / IndustryFinancial Services
Current price$99.52/sh
CompositionInsurance 75% / Reinsurance 25%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed10.0%
Return on equity now16.9%
ROE gap-6.9pp
Price-to-book1.26x

Solve inputs: computed at a 8.8% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026).

How unusual the bet is: within-range

ReferenceValue
vs own history+0.26σ
cohort percentile (of 78 peers)31
sustained it ~10 years at this level76%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.62x3justifies
Earnings0.69x1justifies
Relative0
Growth0

Families that justify the price: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 2.8%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
Bank Fair Value (P/TBV)$184.730.54xyesTBVPS $83.43 × 2.21x (ROE (TTM) 16.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 9.70% allowance/loans → ×0.80)
Relative ValuationRelativenoP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$156.850.63xyesBV/sh $86.55, ROE (TTM) 16.8%, ke 9.3%
Two-Stage Excess ReturnAsset$208.400.48xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowthnoRev $6.7B, growth 11% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelativenoEPS $13.38, growth 35% (input: historical EPS growth), PEG=0.20 (Undervalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$161.420.62xyes√(22.5 × EPS $13.38 × BVPS $86.55) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsnoEPS $13.38 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAssetno
P/Sales SectorRelativeno
PEG Fair ValueRelativenoEPS $13.38 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$144.650.69xyesEPS $13.38 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Insurancefinancialequity$4.3bwithheldunresolved standalone equity facts required
Reinsurancefinancialequity$1.4bwithheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (buyback)-3.3%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Begin with the assumption the market is making, because it is unusually modest. At roughly 1.5 times the book value standing behind the shares, the price is consistent with AXIS earning something close to 11.2% on its equity and holding it. What the company has actually been earning lately is about 16.9%. Nearly the whole bull case lives in that gap, and in the observation that a business does not have to improve at all for the gap to matter. It only has to avoid deteriorating as fast as the price expects.

The earnings come from the right place, which for an insurer means underwriting rather than investing. The combined ratio ran at 89.8% in the first quarter of 2026, meaning claims and expenses together consumed less than ninety cents of every premium dollar. That distinction matters more than it sounds. An insurer that loses money on underwriting and makes it back on the investment portfolio is a leveraged bond fund with a claims department attached. One that profits on the policies themselves earns the investment income as a second, independent stream.

The structural reason it can underwrite that way is where it chooses to compete. Much of the book is written outside the standard filed-rate system, and the filing is explicit about the advantage: writing on a non-admitted or surplus lines basis, which provides flexibility in forms and rates, as these are not filed with state regulators gives the underwriter room to price an unusual risk properly rather than to a template. Governance is built around that discretion rather than in spite of it, with the company describing a disciplined underwriting approach coupled with a peer review process as the mechanism that kept its expansion controlled.

Now compare the outcome with the cohort. AXIS converts about 16.0% of its revenue into profit. CNA converts 8.1%, EG 11.8%, and WRB 12.6%, while ACGL at 24.6% and RLI at 20.8% sit above. That places this company comfortably in the upper half of its peer group on profitability, and yet its multiple of book sits in the lower half of the same group. Better than median results at a cheaper than median price is not a common combination, and it is the specific thing the bull is buying.

Capital allocation reinforces it. The board approved a repurchase programme for up to $ 400 million of the Company's common shares in February 2025, and the share count has fallen about 3.3% a year over the four years to March 2026. A company earning a return well above its cost of equity and simultaneously shrinking its own share count compounds book value per share through the most direct route available, without needing an acquisition or a new market to do it.

The honest concession is that the hard market that produced these returns is over. Rates are softening in property, which is stated plainly above. The counter is what the surplus-lines position is for: the ability to move capacity between lines as pricing moves, rather than defending share in a line that has stopped paying.

Bear Case

The variable with the most leverage over this thesis is not underwriting skill or reserve philosophy. It is the price of insurance itself, and it is falling. The company states the position without decoration: Following multiple years of rate increases outpacing loss cost trends across the specialty sector, overall pricing has moderated and in some sectors is softening. Casualty lines continue to see positive rate achievement while property rates are deteriorating. That single sentence reframes the recent return of about 16.9% on equity. It was earned in the most favourable pricing environment specialty insurers have seen in years, and the environment is now moving the other way.

This is why the bear case here is not an argument that the price is too high. It plainly is not by conventional measures. It is an argument that the market's assumption of roughly 11.2% is the honest one and the recent figure is the cyclical one. If the return settles at the assumed level, today's price is simply correct rather than cheap. If it settles below, the multiple of book compresses from a level that already carries no cushion for that outcome.

A second pressure is arriving on a known schedule and has nothing to do with insurance at all. Bermuda's new corporate tax regime brought a deferred tax benefit that flattered recent earnings, and the company has told shareholders when that runs out: While we anticipated utilizing the Bermuda ETA net deferred tax asset over a ten-year period, guidance issued by the OECD in January 2025 makes it likely that the benefit of the Bermuda ETA net deferred tax asset will only apply in 2025 and 2026. A return on equity supported partly by an accounting benefit with a stated expiry is not the same return on equity that gets extrapolated into a valuation.

Then there is the slow leak that damages insurers more reliably than any hurricane. The filing devotes a risk factor to it: We may be adversely impacted by economic and social inflation. Casualty claims settle years after the premium is collected, so the reserve set today is priced against a legal and medical cost environment that has not happened yet. Evidence that the estimates move is already in the record, with reserve changes attributable to two specific large claims within the E&S book of business related to the 2016 and 2022 accident years. Two claims from a decade ago, still repricing.

Catastrophe exposure is the visible version of the same problem, and it is structurally unpriceable at the tail. The company acknowledges that results could be hurt by disasters which might not have been factored in for the original pricing. For a Bermuda specialty writer with a reinsurance segment attached, that is not a remote scenario. It is the business.

Put the pieces together and the shape is a company whose earnings power is being measured at the top of its own cycle, with a tax tailwind expiring, in lines where reserves take a decade to prove out. The market's discount to what the value-oriented approaches suggest is not obviously an error. It may simply be the market declining to capitalise a peak.

Valuation

An insurer is worth what it earns on the capital it is required to hold, which is why the price gets measured against book value rather than against a multiple of profit. Here the shares change hands at roughly 1.5 times book. Work that backwards and the price is consistent with a sustained return on equity near 11.2%, against something close to 16.9% recently. About 72% of firms earning a return at that level have gone on to hold it for roughly a decade, which is the base rate worth carrying into any judgement about whether the current figure is durable.

The pattern across the valuation approaches is unusual, and it runs in the opposite direction from most reports of this kind. Every family of method lands at or above today's price. The book-value-and-profitability approaches land above it. The earnings-power approaches land further above. The peer-multiple approaches land furthest above of all, though that particular reading leans on an extremely high recent earnings growth input and deserves to be held loosely rather than treated as evidence. Only the forward-projection approaches sit below the price, and only just: the price stands about 12% above where that family of method lands. Nothing here reads as a stretched price; the analytical question is why it is priced where it is, not how it could possibly be justified.

Part of the answer sits in the scale and shape of the balance sheet. The company describes total capital of $7.7 billion and total assets of $34.5 billion against a market value considerably smaller than that capital base would suggest at peer multiples. For a financial, ordinary balance-sheet arithmetic does not apply: the liabilities are reserves against future claims rather than borrowings, so leverage ratios and interest coverage measure nothing useful. The test that matters is whether the capital is adequate to the risk being written and whether earnings can be returned without eroding it.

On the second half of that test the record is direct. The board authorised a repurchase programme for up to $ 400 million of the Company's common shares in February 2025, and the share count has fallen roughly 3.3% a year across the four years to March 2026. Capital is being handed back rather than deployed into growth, which is consistent with a management team that judges the current pricing environment to be a poor place to add exposure.

The figure that would move this analysis is none of the above. It is prior-year reserve development. Book value is the denominator in every reading of this price, and reserves held against accident years going back to 2016 are the largest discretionary estimate inside it. Adverse movement there reduces the book the price is measured against and the earnings in the same period, which is why the reserve line rather than the premium line is the one that decides whether today's multiple of book turns out to have been low.

Catalysts

The next scheduled event is close. Second-quarter 2026 results are due after the close on Tuesday, July 28, 2026, with the investor call the following morning.

The first quarter set the bar. Net income available to common shareholders came to $3.29 a diluted share, with a combined ratio of 89.8% and gross premiums written of roughly 3.1 billion dollars. A combined ratio below ninety in a softening market is the specific thing the bull case rests on, and it is also the thing most exposed to the pricing trend the company itself describes.

Two items are worth separating when the quarter lands. The first is whether the combined ratio holds without help from favourable development on older accident years, since underwriting profit borrowed from prior reserves is not the same as underwriting profit earned on current business. The second is the tax line, which carries a Bermuda deferred benefit the company has said is likely to apply only through 2026. Both are visible in the release rather than requiring an analyst's reconstruction, and both bear directly on whether the recent return on equity is a run rate or a peak.

Peer Cohorts (Per Segment, With Filing Citations)

Insurance (reported)

Reinsurance (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company announcement, July 2026 · Q1 2026 results release

View the full interactive AXS report on boothcheck